GlassScriptPhysician profile
Ghulam Dostzada
NPI 1093778649
$1,767.12
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $225 · 2021: $555 · 2022: $450 · 2023: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.62 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $277.51 | 2020-2022 | |
| Amgen INC. | $179.87 | 2019-2021 | |
| Irhythm Technologies, INC. | $61.45 | 2022 | |
| Boston Scientific Corporation | $55.75 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $55.39 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.90 | 2020-2022 | |
| Pfizer INC. | $35.70 | 2022 | |
| Csl Behring | $24.79 | 2020 | |
| Merck Sharp & Dohme LLC | $23.19 | 2022 | |
| Organogenesis INC. | $22.20 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.17 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $21.99 | 2023 | Arcalyst |
| Lundbeck LLC | $20.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.00 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bsn Medical INC | $15.53 | 2019 | |
| Esperion Therapeutics, INC. | $14.79 | 2020 | |
| Atricure, INC. | $14.77 | 2021 | |
| Medtronic, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Dostzada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.